Current Psychiatry Reports

, Volume 12, Issue 6, pp 563–571 | Cite as

Assessment of Pharmacotherapy for Negative Symptoms of Schizophrenia

  • Elizabeth Hanson
  • Kristin Healey
  • Daniel Wolf
  • Christian Kohler


Negative symptoms in schizophrenia include diminished ability to communicate, motivate, and socialize as potentially debilitating aspects of the illness that are associated with long-term impairment. Despite such burden, the domain has been underrepresented in drug development and treatment research. In this article, we review research regarding pharmacotherapy for negative symptoms, with a focus on studies published during the past 2 years. Clearly positive studies were limited to N-methyl-D-aspartate agonists, while antipsychotics and antidepressants did not show substantial benefit, and cognitive enhancers have yielded mixed results. Proof-of-concept studies of other agents such as minocycline and omega fatty acids yielded promising, albeit preliminary findings that warrant replication. Study outcomes and designs are discussed along with implications for future research.


Schizophrenia Negative symptoms Treatment Pharmacotherapy NMDA agonist 


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Liddle P: The symptoms of chronic schizophrenia: a reexamination of the positive–negative dichotomy. Br J Psychiatry 1987, 151:145–151.CrossRefPubMedGoogle Scholar
  2. 2.
    Milev P, Ho BC, Arndt S, Andreasen NC: Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry 2005, 162:495–506.CrossRefPubMedGoogle Scholar
  3. 3.
    Buchanan RW, Davis M, Goff D, et al.: A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull 2005, 31:5–19.CrossRefPubMedGoogle Scholar
  4. 4.
    Andreasen NC: The Scale for the Assessment of Negative Symptoms (SANS). Iowa City, IA: University of Iowa; 1983.Google Scholar
  5. 5.
    Kay SR, Fiszbein A, Opler LA: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987, 13:261–276.PubMedGoogle Scholar
  6. 6.
    Overall JE, Gorham DR: The Brief Psychiatric Rating Scale. Psychol Rep 1962, 10:799–812.CrossRefGoogle Scholar
  7. 7.
    Kirkpatrick RW, Buchanan PD, McKenney LD, et al.: The Schedule for the Deficit Syndrome: an instrument for research in schizophrenia. Psychiatry Res 1989, 30:119–123.CrossRefPubMedGoogle Scholar
  8. 8.
    Alphs L, Summerfelt A, Lan H, Muller RJ: The Negative Symptom Assessment: a new instrument to assess negative symptoms of schizophrenia. Psychopharmacol Bull 1989, 25:159–163.PubMedGoogle Scholar
  9. 9.
    Juckel G, Schlagenhauf F, Koslowski M, et al.: Dysfunction of ventral striatal reward prediction in schizophrenia. Neuroimage 2006, 29:409–416.CrossRefPubMedGoogle Scholar
  10. 10.
    Gur RE, Loughead J, Kohler, CG, et al.: Limbic activation associated with misidentification of fearful faces and flat affect in schizophrenia. Arch Gen Psychiatry 2007, 64:1356–1366.CrossRefPubMedGoogle Scholar
  11. 11.
    Sepehry AA, Potvin S, Élie R, Stip E: SSRI add-on therapy for the negative symptoms of schizophrenia: a meta-analysis. J Clin Psychiatry 2007, 68:604–610.CrossRefPubMedGoogle Scholar
  12. 12.
    Zoccali R, Muscatello MR, Bruno A, et al.: The effect of lamotrigine augmentation of clozapine in a sample of treatment-resistant schizophrenic patients: a double-blind, placebo-controlled study. Schizophr Res 2007, 93:109–116.CrossRefPubMedGoogle Scholar
  13. 13.
    Potkin SG, Litman RE, Torres R, Wolfgang CD: Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. J Clin Psychopharmacol 2008, 28:S4–S11.CrossRefPubMedGoogle Scholar
  14. 14.
    Thompson A, Lavedan C, Volpi S: Absence of weight gain association with the HTRC-759C/T polymorphism in patients with schizophrenia treated with iloperidone. Psychiatr Res 2010, 165:271–273.CrossRefGoogle Scholar
  15. 15.
    Volpi S, Potkin SG, Malhotra AK, et al.: Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia. J Clin Psychiatry 2009, 70:801–809.CrossRefPubMedGoogle Scholar
  16. 16.
    Emsley R, Doelder PD, Schoemaker J, Naber D: Long-term safety of asenapine in patients with schizophrenia. Schizophr Res 2008, 98(Suppl):1–48.Google Scholar
  17. 17.
    Weber J, McCormack PL: Asenapine. CNS Drugs 2009, 23:781–792.CrossRefPubMedGoogle Scholar
  18. 18.
    Zoccali R, Muscatello MR, Cedro C, et al.: The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double-blind, placebo-controlled study. Int Clin Psychopharmacol 2004, 19:71–76.CrossRefPubMedGoogle Scholar
  19. 19.
    Berk M, Ichim C, Brook S: Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. Int Clin Psychopharmacol 2001, 16:87–92.CrossRefPubMedGoogle Scholar
  20. 20.
    Abbasi SH, Behpournia H, Ghoreshi A, et al.: The effect of mirtazapine add on therapy to risperidone in the treatment of schizophrenia: a double-blind randomized placebo-controlled trial. Schizophr Res 2010, 116:101–106.CrossRefPubMedGoogle Scholar
  21. 21.
    Joffe G, Terevnikov V, Joffe M, et al.: Add-on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double-blind, randomized, placebo-controlled trial. Schizophr Res 2009, 108:245–251.CrossRefPubMedGoogle Scholar
  22. 22.
    Berk M, Gama CS, Sundram S, et al.: Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomized, placebo-controlled clinical trial. Hum Psychopharmacol Clin Exp 2009, 24:233–238.CrossRefGoogle Scholar
  23. 23.
    Berk M, Ichim C, Brook S: Efficacy of mirtazapine add-on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. Int Clin Psychopharmacol 2001, 16:87–92.CrossRefPubMedGoogle Scholar
  24. 24.
    Zisook S, Kasckow JW, Golshan S, et al.: Citalopram augmentation for subsyndromal symptoms of depression in middle-aged and older outpatients with schizophrenia and schizoaffective disorder: a randomized controlled trial. J Clin Psychiatry 2009, 70:562–571.CrossRefPubMedGoogle Scholar
  25. 25.
    Poyurovsky M, Faragian S, Fuchs C, et al.: Effect of the selective norepinephrine reuptake inhibitor reboxetine on cognitive dysfunction in schizophrenia patients: an add-on, double-blind placebo-controlled study. Isr J Psychiatry Relat Sci 2009, 46:213–220.PubMedGoogle Scholar
  26. 26.
    Sumiyoshi T, Park S, Jayathilake K, et al.: Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res 2007, 95:158–168.CrossRefPubMedGoogle Scholar
  27. 27.
    Piskulic D, Olver JS, Maruff P, Norman TR: Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5-HT1A receptor agonist. Hum Psychopharmacol 2009, 24:437–446.CrossRefPubMedGoogle Scholar
  28. 28.
    Freedman R, Hall M, Adler LE, Leonard S: Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry 1995, 38:22–33.CrossRefPubMedGoogle Scholar
  29. 29.
    Breese CR, Lee MJ, Adams CE, et al.: Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacology 2000, 23:351–364.CrossRefPubMedGoogle Scholar
  30. 30.
    Akhondzadeh S, Gerami M, Noroozian M, et al.: A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2008, 32:1810–1815.CrossRefPubMedGoogle Scholar
  31. 31.
    Conley RR, Boggs DL, Kelly DL, et al.: The effects of galantamine on psychopathology in chronic stable schizophrenia. Clin Neuropharmacol 2009, 32:69–74.CrossRefPubMedGoogle Scholar
  32. 32.
    Lieberman JA, Papadakis K, Csernansky J, et al.: A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. Neuropsychopharmacology 2009, 34:1322–1329.CrossRefPubMedGoogle Scholar
  33. 33.
    De Lucena D, Fernandes BS, Berk M, et al.: Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine. J Clin Psychiatry 2009, 70:1416–1423.CrossRefPubMedGoogle Scholar
  34. 34.
    Sacco KA, Creeden C, Reutenauer EL, et al.: Effects of atomoxetine on cognitive function and cigarette smoking in schizophrenia. Schizophr Res 2009, 107:332–333.CrossRefPubMedGoogle Scholar
  35. 35.
    Kelly DL, Buchanan RW, Boggs DL, et al.: A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia. J Clin Psychiatry 2009, 70:518–525.CrossRefPubMedGoogle Scholar
  36. 36.
    Freudenreich O, Henderson DC, Macklin EA, et al.: Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial. J Clin Psychiatry 2009, 70:1674–1680.CrossRefPubMedGoogle Scholar
  37. 37.
    Turner DC, Clark I, Pomarol-Clotet E, et al.: Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia. Neuropsychopharmacology 2004, 29:1363–1373.CrossRefPubMedGoogle Scholar
  38. 38.
    Krystal JH, Karper LP, Seibyl JP, et al.: Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994, 51:199–214.PubMedGoogle Scholar
  39. 39.
    Quartermain D, Mower J, Rafferty MF, et al.: Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention. Eur J Pharmacol 1994, 257:7–12.CrossRefPubMedGoogle Scholar
  40. 40.
    Goff DC, Cather C, Gottlieb JD, et al.: Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study. Schizophr Res 2008, 106:320–327.CrossRefPubMedGoogle Scholar
  41. 41.
    • Lane HY, Lin CH, Huang YJ, et al.: A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia. Int J Neuropsychopharmacol 2010, 13:451–460. Sarcosine represents an intermediate byproduct in glycine metabolism. Blocking the glycine transporter increases glycine concentrations in the brain and enhances NMDA receptor functioning. In 60 individuals with chronic schizophrenia in this study, sarcosine improved negative symptoms and quality of life as compared with serine and placebo.CrossRefPubMedGoogle Scholar
  42. 42.
    Marx CE, Keefe RSE, Buchanan RW, et al.: Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. Neuropsychopharmacology 2009, 34:1885–1903.CrossRefPubMedGoogle Scholar
  43. 43.
    Kulkarni J, Gurvich C, Lee SJ, et al.: Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia. Psychoneuroendocrinology 2010, 35:1142–1147.CrossRefPubMedGoogle Scholar
  44. 44.
    • Levkovitz Y, Mendlovich S, Riwkes S, et al.: A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry 2010, 71:138–149. Minocycline, a second-generation tetracycline, has been found to exert neuroprotective effects in animal studies via effects on the NMDA receptor complex. In this study, 70 individuals with early-phase schizophrenia were randomly assigned to minocycline versus placebo for 5 months. Minocycline was well-tolerated and improved negative symptoms and executive functioning.CrossRefPubMedGoogle Scholar
  45. 45.
    Glick ID, Bosch J, Casey DE: A double-blind randomized trial of mood stabilizer augmentation using lamotrigine and valproate for patients with schizophrenia who are stabilized and partially responsive. J Clin Psychopharmacol 2009, 29:267–271.CrossRefPubMedGoogle Scholar
  46. 46.
    McGorry PD, Yung AR, Phillips LJ, et al.: Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 2002, 59:921–928.CrossRefPubMedGoogle Scholar
  47. 47.
    McGlashan TH, Zipursky RB, Perkins D, et al.: Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 2006, 163:790–799.CrossRefPubMedGoogle Scholar
  48. 48.
    Freeman MP, Hibbeln JR, Wisner KL, et al.: Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. J Clin Psychiatry 2006, 67:1954–1967.CrossRefPubMedGoogle Scholar
  49. 49.
    Joy CB, Mumby-Croft R, Joy LA: Polyunsaturated fatty acid supplementation for schizophrenia. Cochrane Database Syst Rev 2006, 3:CD001257.PubMedGoogle Scholar
  50. 50.
    •• Amminger GP, Schafer MR, Papageorgiou K, et al.: Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders. Arch Gen Psychiatry 2010, 67:146–154. Conversion to psychosis in young individuals at clinical risk of schizophrenia represents a major treatment goal. Dysfunctional fatty acid metabolism may contribute to the etiology of schizophrenia. In 81 young individuals with subthreshold symptoms of psychosis in this study, polyunsaturated fatty acid augmentation for 12 weeks was associated with decreased risk of progression to psychosis over 1 year.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Elizabeth Hanson
    • 1
  • Kristin Healey
    • 1
  • Daniel Wolf
    • 1
  • Christian Kohler
    • 1
  1. 1.Schizophrenia Research Center, Department of Psychiatry University of Pennsylvania School of MedicineHospital of the University of PennsylvaniaPhiladelphiaUSA

Personalised recommendations